Featured Products
Our Promise to You
Guaranteed product quality, expert customer support
ONLINE INQUIRY
Immortalized Human Skeletal Muscle Myoblasts
Cat.No.: CSC-I9102L
Species: homo sapiens
Source: Skeletal Muscle
Morphology: Multipolar
Culture Properties: Adherent
- Specification
- Q & A
- Customer Review
Note: Never can cells be kept at -20 °C.
CIK-HT013 HT® Lenti-hTERT Immortalization Kit
CIK-HT003 HT® Lenti-SV40T Immortalization Kit
Each order includes a Certificate of Analysis, detailed usage instructions, and a culture manual. Additionally, our experienced technical support team is available to assist with any questions or challenges that may arise during your research.
Yes, Immortalized Human Skeletal Muscle Myoblasts-SV40T are capable of differentiating into myotubes. This process requires the use of a specialized differentiation medium, which is available for purchase separately.
Ask a Question
Write your own review
Description: Microglia cells are resident macrophages of the brain and spinal cord and they act as the first and the main form of active immune defense in the nervous system. The Immortalized Human Microglia - SV40 cell line is derived from Primary Human Microglia Cells (>99% purity) and have maintained microglial marker TREM2 as demonstrated by RT-PCR. These cells are suitable for studies of human microglia in health and disease.
Description: Immortalized Human Umbilical Vein Endothelial Cells-hTERT were developed from human tissues transduced with a lentiviral expression vector containing the hTERT gene. The cell line was continuously cultured for more than 20 passages without showing signs of growth retardation or replicative senescence. The Immortalized Human Umbilical Vein Endothelial Cells are useful for setting up in vitro bioassays for studying angiogenesis in e.g. wound healing or metastasis as well as bioassays for testing the angiogenic properties of novel drugs. Additionally, the cell line is the perfect starting material for genetic engineering to create important disease models.
